Last reviewed · How we verify
NCT03190031: MUCOMUREE
Respiratory Muscle Training in CF Patients
NA trial testing Endurance respiratory muscle training in Cystic Fibrosis in 38 participants. Completed in 30 December 2019.
30 December 2019
Quick facts
| Lead sponsor | University Hospital, Grenoble |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 1 February 2017 |
| Primary completion | 30 December 2019 |
| Estimated completion | 30 December 2019 |
| Sites | 1 location across France |
Drugs / interventions tested
- Endurance respiratory muscle training
- Resistance inspiratory muscle training
Conditions studied
- Cystic Fibrosis — all drugs for Cystic Fibrosis →
- Respiratory Muscles — all drugs for Respiratory Muscles →
Sponsor
University Hospital, Grenoble
Who can join
Adults 18 to 60, any sex, with Cystic Fibrosis or Respiratory Muscles. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present study aims at evaluating the effect of respiratory muscle training in adult patients with cystic fibrosis on lung function, exercise performance and quality of life.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Respiratory muscle training for cystic fibrosis.
Stanford G, Ryan H, Solis-Moya A. · · 2020 · cited 11× · PMID 33331663 · DOI 10.1002/14651858.cd006112.pub5
Verify or expand the search:
- PubMed search for NCT03190031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cystic Fibrosis
Currently open trials in the same condition.
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
- NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting
Other University Hospital, Grenoble trials
Trials by the same sponsor.
- NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
- NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
- NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
- NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
- NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03190031 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
- Last refreshed: 23 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03190031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing